Kalender
| Est. tid* | ||
| 2026-08-26 | 08:30 | Kvartalsrapport 2026-Q2 |
| 2026-05-27 | N/A | Årsstämma |
| 2026-05-13 | 08:30 | Kvartalsrapport 2026-Q1 |
| 2026-02-11 | 10:30 | Bokslutskommuniké 2025 |
| 2025-11-12 | 08:30 | Kvartalsrapport 2025-Q3 |
| 2025-08-27 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-30 | - | X-dag ordinarie utdelning QLIFE 0.00 SEK |
| 2025-05-28 | - | Årsstämma |
| 2025-05-20 | - | Kvartalsrapport 2025-Q1 |
| 2025-03-21 | - | Extra Bolagsstämma 2025 |
| 2025-02-12 | - | Bokslutskommuniké 2024 |
| 2024-11-07 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-29 | - | Kvartalsrapport 2024-Q2 |
| 2024-07-30 | - | Split QLIFE 2000:1 |
| 2024-05-28 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-08 | - | X-dag ordinarie utdelning QLIFE 0.00 SEK |
| 2024-05-07 | - | Årsstämma |
| 2024-02-08 | - | Bokslutskommuniké 2023 |
| 2024-01-16 | - | Extra Bolagsstämma 2023 |
| 2023-11-13 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-17 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-26 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-05 | - | X-dag ordinarie utdelning QLIFE 0.00 SEK |
| 2023-05-04 | - | Årsstämma |
| 2023-03-24 | - | Extra Bolagsstämma 2022 |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-11-25 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-29 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-06 | - | X-dag ordinarie utdelning QLIFE 0.00 SEK |
| 2022-05-05 | - | Årsstämma |
| 2022-05-05 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-11-08 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-16 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-06 | - | X-dag ordinarie utdelning QLIFE 0.00 SEK |
| 2021-05-05 | - | Årsstämma |
| 2021-05-05 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-11-19 | - | Extra Bolagsstämma 2020 |
| 2020-11-18 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-18 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-22 | - | X-dag ordinarie utdelning QLIFE 0.00 SEK |
| 2020-05-20 | - | Årsstämma |
| 2020-05-20 | - | Kvartalsrapport 2020-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Qlife Holding AB ("Qlife" or the "Company") announces an extension of the Letter of Intent regarding a potential reverse takeover (the "Transaction") with Hipro Biotechnology Co., Ltd. ("Hipro"). The Transaction was announced by the Company through a press release on 5 June 2025. The term and exclusivity of the Letter of Intent have been extended, and the Transaction would be conditional upon, inter alia, the signing of a share purchase agreement no later than 31 December 2025. The other material terms and conditions of the Transaction as previously communicated by the Company remain unchanged.
The parties remain fully committed to the strategic rationale of the transaction and are aligned in their intent to execute it as outlined in the Letter of Intent.
For more information about the intended terms of the Transaction, please refer to the press release that was published on 5 June 2025 "Qlife Holding AB: Qlife enters letter of intent with Hipro Biotechnology Co., Ltd. to join forces through a reverse takeover".
For more information, please contact:
Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34
About Qlife
Qlife is a Swedish company based in Göteborg, which develops and markets an innovative medical technology platform, Egoo.Health ("Egoo"), with the goal of giving people access to clinical biomarker data when testing at home. The company is listed on the Nasdaq First North Growth Market (ticker: QLIFE). G&W Fondkommission is the Company's Certified Adviser. For additional information, please visit www.qlifeholding.com.